New drug aims to tame rare blood disorder flares

NCT ID NCT04191304

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This Phase 3 study tests whether benralizumab, a biologic injection given every 4 weeks, can reduce flares in people with hypereosinophilic syndrome (HES), a rare condition where too many eosinophils cause organ damage. About 134 patients aged 12 and older will receive either benralizumab or a placebo for 24 weeks, followed by an open-label extension where everyone gets the drug. The main goal is to see how long it takes for a flare to occur.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Benralizumab (a biologic drug given as an injection every 4 weeks)
What this could lead to: If it works, this could provide a new treatment option to reduce flares and control symptoms for people with hypereosinophilic syndrome.
What could go wrong: This is a Phase 3 trial, but results are not yet final. The drug may not work better than placebo, and side effects are possible. The study is also relatively small (134 participants).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypereosinophilic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPEREOSINOPHILIC SYNDROME

Contacts and locations

Locations

Research Site

La Jolla, California, 92037, United States
Research Site

Atlanta, Georgia, 30324, United States
Research Site

Bethesda, Maryland, 20892, United States
Research Site

Ann Arbor, Michigan, 48105, United States
Research Site

Durham, North Carolina, 27705, United States
Research Site

Cleveland, Ohio, 44106, United States
Research Site

Columbus, Ohio, 43212, United States
Research Site

Salt Lake City, Utah, 84112, United States
Research Site

Rosario, 2000, Argentina
Research Site

Innsbruck, 6020, Austria
Research Site

Brussels, 1070, Belgium
Research Site

Edegem, 2650, Belgium
Research Site

Chengdu, 610041, China
Research Site

Shanghai, 200040, China
Research Site

Tianjin, 300020, China
Research Site

Xiamen, 361015, China
Research Site

Zhengzhou, 450008, China
Research Site

København Ø, 2100, Denmark
Research Site

Lille, 59037, France
Research Site

Pessac, 33604, France
Research Site

Strasbourg, 67091, France
Research Site

Suresnes, 92151, France
Research Site

Toulouse, 31059, France
Research Site

Hanover, 30625, Germany
Research Site

Kirchheim, 73230, Germany
Research Site

Mannheim, 68167, Germany
Research Site

Ahmedabad, 380013, India
Research Site

Ajmer, 305001, India
Research Site

Delhi, 110029, India
Research Site

Haifa, 34362, Israel
Research Site

Holon, 58100, Israel
Research Site

Jerusalem, 91120, Israel
Research Site

Kfar Saba, 44218, Israel
Research Site

Petah Tikva, 49100, Israel
Research Site

Ramat Gan, 5265601, Israel
Research Site

Rehovot, 76100, Israel
Research Site

Tel Aviv, 64239, Israel
Research Site

Bologna, 40138, Italy
Research Site

Chiba, 260-0852, Japan
Research Site

Hamamatsu, 431-3192, Japan
Research Site

Ichikawa-shi, 272-8516, Japan
Research Site

Kawasaki-shi, 211-8510, Japan
Research Site

Nishinomiya-shi, 663-8501, Japan
Research Site

Osaka, 530-8480, Japan
Research Site

Sendai, 980-8574, Japan
Research Site

Rotterdam, 3015 GD, Netherlands
Research Site

Chęciny, 26-060, Poland
Research Site

Gdansk, 80-214, Poland
Research Site

Lodz, 90-153, Poland
Research Site

Seoul, 5505, South Korea
Research Site

Santander, 39010, Spain
Research Site

London, W2 1NY, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.